[CAS NO. 459147-39-8] SW033291
PRODUCTS SPECIFICATIONS [459147-39-8]
DESCRIPTION [459147-39-8]
Overview
| MDL | MFCD02973087 |
|---|---|
| Molecular Weight | 412.59 |
| Molecular Formula | C21H20N2OS3 |
| SMILES | NC1=C(S(CCCC)=O)SC2=NC(C3=CC=CS3)=CC(C4=CC=CC=C4)=C21 |
3 Publications Citing Use of MCE
Summary
IC50 & Target
Ki: 0.1 nM (15-PGDH) [1]
In Vitro
Treating cells with SW033291 decreases cellular 15-PGDH enzyme activity by 85%. SW033291 inhibition of 15-PGDH was non-competitive versus PGE2 over concentrations up to 40 μM PGE2. Treatment of A549 cells with SW033291 increases PGE2 levels by 3.5-fold at 500 nM, with an EC 50 50 at approximately 75 nM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SW033291 (10 mg/kg; intraperitoneal injection; twice daily; for 3 days; C57BL/6J mice) treatment for three consecutive days shows significant benefits, including a doubling of peripheral neutrophil counts, a 65% increase in marrow SKL cells, and a 71% increase in marrow SLAM cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6J mice [1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; twice daily; for 3 days ( for 5 doses) |
| Result: | Showed significant benefits, including a doubling of peripheral neutrophil counts, a 65% increase in marrow SKL cells, and a 71% increase in marrow SLAM cells. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 33.33 mg/mL ( 80.78 mM ; ultrasonic and warming and heat to 70°C)
Ethanol : 25 mg/mL ( 60.59 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4237 mL | 12.1186 mL | 24.2371 mL |
| 5 mM | 0.4847 mL | 2.4237 mL | 4.8474 mL |
| 10 mM | 0.2424 mL | 1.2119 mL | 2.4237 mL |